Transarterial chemoembolization combined with sorafenib and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombus:a retrospective controlled study  

作　　者：Jingjun Huang Mingyue Cai Wensou Huang Yongjian Guo Jingwen Zhou Licong Liang Liteng Lin Zhimei Zhou Hui Lian Mingji He Kangshun Zhu 

机构地区：[1]Department of Minimally Invasive Interventional Radiology,The Second Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong 510260,China [2]Department of Radiology,The Second Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong 510260,China

出　　处：《Chinese Medical Journal》2022年第1期113-115,共3页中华医学杂志（英文版）

基　　金：This work was supported by grants from the National Natural Science Foundation of China(Nos.81873920,81571774);the High-Level University Clinical Research Promotion Program of Guangzhou Medical University(No.B185004019);the Science and Technology Project of Guangzhou(No.202002030135);the Medical Science and Technology Research Foundation of Guangdong Province(Nos.A2019187,B2019055,and B2019089)。

摘　　要：To the Editor:Portal vein tumor thrombus(PVTT)is present in 10%to 40%of patients with hepatocellular carcinoma(HCC)at diagnosis and has a profound adverse effect on progno-sis.[1]Sorafenib is recommended as the first-line treatment for patients with advanced HCC,including those who have PVTT.However,its efficacy is modest.[1,2]A combination of transarterial chemoembolization(TACE)and sorafenib(TACE-S)has been reported to be associated with improved outcomes.[1,3]But unfortunately,its efficacy in controlling PVTT remained limited,with an objective response rate(ORR)of only 9.7%.[3]Previous studies have demonstrated that iodine-125(125I)seed brachytherapy targeting PVTT can lead to a significant reduction in tumor thrombus with few complications.[4,5]We hypothesized that TACE-S combined with 125I seed brachytherapy(TACE-S-I)could improve the control of PVTT and confer a greater survival benefit.Therefore,we conducted this study to evaluate the efficacy and safety of TACE-S-I compared with TACE-S in HCC patients with PVTT.This study was approved by our institutional review board(No.2020-hg-ks-03).

关 键 词：ARTERIAL SORAFENIB diagnosis 

分 类 号：R735.7[医药卫生—肿瘤]